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Abstract
Merkel cell carcinoma (MCC) is an aggressive skin cancer with a high propensity for recur-
rence and metastasis. Merkel cell polyomavirus (MCPyV) is recognised as the causative
factor in the majority of MCC cases. The MCPyV small tumour antigen (ST) is considered to
be the main viral transforming factor, however potential mechanisms linking ST expression
to the highly metastatic nature of MCC are yet to be fully elucidated. Metastasis is a complex
process, with several discrete steps required for the formation of secondary tumour sites.
One essential trait that underpins the ability of cancer cells to metastasise is how they
interact with adjoining tumour cells and the surrounding extracellular matrix. Here we dem-
onstrate that MCPyV ST expression disrupts the integrity of cell-cell junctions, thereby
enhancing cell dissociation and implicate the cellular sheddases, A disintegrin and metallo-
proteinase (ADAM) 10 and 17 proteins in this process. Inhibition of ADAM 10 and 17 activity
reduced MCPyV ST-induced cell dissociation and motility, attributing their function as critical
to the MCPyV-induced metastatic processes. Consistent with these data, we confirm that
ADAM 10 and 17 are upregulated in MCPyV-positive primary MCC tumours. These novel
findings implicate cellular sheddases as key host cell factors contributing to virus-mediated
cellular transformation and metastasis. Notably, ADAM protein expression may be a novel
biomarker of MCC prognosis and given the current interest in cellular sheddase inhibitors
for cancer therapeutics, it highlights ADAM 10 and 17 activity as a novel opportunity for tar-
geted interventions for disseminated MCC.
Author summary
The majority of cancer-related deaths occur due to metastatic disease. Therefore, under-
standing the molecular and cellular mechanisms underlying the process of metastasis is
essential to developing new therapeutic interventions to improve cancer patient survival.
Merkel cell carcinoma (MCC) is an aggressive and highly metastatic cancer. Merkel cell
polyomavirus (MCPyV) has been implicated as the causative agent in the majority of
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MCC cases. The MCPyV small tumour antigen (ST) is believed to function as the major
oncoprotein. However, little is known about the mechanisms through which MCPyV ST
may be implicated in causing the high rates of metastatic spread observed in MCC
tumours. Here we show that specific cellular sheddases, namely A disintegrin and metallo-
proteinase (ADAM) 10 and 17 protein levels are increased upon MCPyV ST expression.
Moreover, we show that MCPyV ST-induced ADAM 10 and 17 are required to break-
down cell-cell junctions resulting in increased cell dissociation, migration and invasion.
As such, ADAM protein expression may provide a novel biomarker of MCC prognosis.
In addition, linking cellular sheddases to MCPyV-positive MCC metastasis may provide
novel therapeutic interventions.
Introduction
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine cancer of the skin [1].
Although rare, the incidence of MCC has increased over the past twenty years in both Europe
and the United States of America [2], attributed to advances in reporting, diagnostic improve-
ments and known risk factors. UV light appears to be an important factor in MCC, with a pos-
itive correlation between geographic UVB radiation indices and age-adjusted MCC amongst
Caucasians [1, 3]. The predominance of MCC in elderly persons also highlights immunosup-
pression as an important risk factor, supported by disproportionally higher rates of MCC in
patients on long-term iatrogenic immunosuppression, in addition to patients with lymphopro-
liferative disorders and HIV/AIDs [2]. Due to its aggressive nature MCC carries a high risk of
local, regional and distant recurrence [4]. As such, the 5-year survival rates range from 60–
87% for local disease to 11–20% for metastatic disease [5–7].
The majority of MCC cases, ~80%, are associated with Merkel cell polyomavirus (MCPyV)
[8], whilst the remaining cases contain a high degree of single nucleotide polymorphisms con-
sistent with UV-mediated mutations [9, 10]. MCPyV is a common skin commensal causing an
asymptomatic infection usually acquired in childhood. Like other polyomaviruses, MCPyV
expresses a variety of early spliced variant regulatory proteins required for viral replication and
pathogenesis, including the small and large tumour antigens (ST and LT, respectively) [11].
Upon loss of immunosurveillance, the MCPyV genome integrates into the host genome prior
to clonal expansion of tumour cells [12, 13]. A further prerequisite for MCPyV-mediated
tumourigenesis is the truncation of the LT antigen rendering the virus replication defective
[13]. These truncations lead to the loss of functional LT domains associated with virus replica-
tion, although all preserve the LXCXE Retinoblastoma (Rb) protein-binding domain, which
alters cell cycle progression contributing to increased cell proliferation [14, 15].
Both MCPyV ST and truncated LT antigens are essential for MCC cell survival and prolifer-
ation, exemplified by siRNA-mediated depletion of either protein leading to cell cycle arrest
and apoptosis [16]. Moreover, genetically engineered mice expressing MCPyV T antigens in
the stratified epithelium display signs of neoplastic progression [17]. However, in contrast to
the prototype polyomavirus, simian virus 40 (SV40), MCPyV truncated LT forms cannot initi-
ate cellular transformation alone and function in an accessory role by binding host factors
which regulate cellular proliferation, such as Rb and Hsc70 [18, 19]. Conversely, MCPyV ST
expression is sufficient to transform rodent cells to anchorage- and contact-independent
growth and induce serum-free proliferation of human cells [18]. In addition, preterm trans-
genic mice co-expressing epidermis-tagged MCPyV ST and the cell fate determinant atonal
bHLH transcription factor 1 developed widespread cellular aggregates representative of
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human intraepidermal MCC [20]. Together these observations show that MCPyV ST is the
major oncogenic driver of MCC. Several MCPyV ST-mediated mechanisms contribute to
MCC development and proliferation. ST expression leads to the hyperphosphorylation of the
translation regulatory protein, 4E-BP1, resulting in dysregulation of cap-dependent translation
[18] and prevents SCFFwb7-mediated degradation of MCPyV LT and several cellular oncopro-
teins [21]. It induces centrosome overduplication, aneuploidy, chromosome breakage and the
formation of micronuclei by targeting cellular E3 ubiquitin ligases [22]. MCPyV ST also func-
tions as an inhibitor of NF-κB-mediated transcription [23, 24]. Moreover, ST activates gene
expression by associating with MYCL and the EP400 histone and chromatin remodelling com-
plex [25], inducing transcriptional changes effecting for example glycolytic metabolic path-
ways [26].
The poor survival rates of MCC strongly correlate to the high dissemination rates and meta-
static nature of MCC [5]. Whether MCPyV T antigens contribute to MCC metastasis is yet to
be fully elucidated. Metastasis is a complex process, with several discrete steps required for the
formation of secondary tumour sites [27]. These metastatic hallmarks include loss of cell adhe-
sion, gain of cell motility, dissemination via the vasculature, and colonisation of distant sites
[28, 29]. Recent quantitative proteomic studies suggest MCPyV ST expression can promote
cell motility and migration [30–32] by inducing differential expression of cellular proteins
involved in microtubule [30] and actin-associated cytoskeletal organization and dynamics
[31], leading to microtubule destabilization and filopodium formation. These results suggest
that MCPyV may be associated with the highly metastatic nature of MCC, and is supported by
studies showing that engraftment of MCC cell lines into SCID mice results in circulating
tumour cells and metastasis formation [33].
One key trait that underpins the ability of cancer cells to become invasive and metastasise is
how they interact with the surrounding extracellular matrix (ECM) and adjoining tumour and
stromal cells [34, 35]. Cell–cell junctions are sites of intercellular adhesion that maintain the
integrity of epithelial tissue and regulate signalling between cells [36]. The expression of cell
adhesion molecules is tightly regulated, as dysregulation of cell adhesion between tumour cells
and turnover of the surrounding ECM plays a critical role in malignant transformation and
the initiation of the metastatic cascade [37]. A key mediator of cell adhesion in epithelial tissues
is E-cadherin and its loss can promote invasive and metastatic behaviour in many epithelial
tumours [38]. The cytoplasmic domain of E-cadherin binds to members of the catenin family,
linking this multiple protein complex to the actin cytoskeleton through alpha-E-catenin. The
clustering of cadherin-catenin complexes on adjacent cells leads to localised actin remodelling
required for the formation of adheren junctions [39]. Notably, the loss of E-cadherin and asso-
ciated cell adhesion molecules, results in the suppression or weakening of cell–cell adhesion
which is regarded as a crucial step in the epithelial–mesenchymal transition (EMT) [40, 41], a
process enabling a cell to acquire a more migratory and invasive mesenchymal phenotype.
Loss of E-cadherin and associated cell adhesion molecules in human tumours is caused by
multiple factors, including germline mutations, promoter methylation, downregulation of
EMT-associated transcriptional repressor proteins and the upregulation of cellular proteinases
causing proteolytic cleavage of cell adhesion molecules [42–44].
ADAMs (a disintegrin and metalloproteinases), are a family of zinc-dependent transmem-
brane proteins implicated in the ectodomain shedding of various membrane-bound proteins
[45]. Of the 21 human largely cell-membrane associated ADAMs, 13 have proteolytic sheddase
capacities modulating the activity of membrane cytokines and growth factors, their receptors
and cell adhesion molecules, including cadherins, selectins and integrins [46]. ADAM shed-
dase activities have been implicated in several physiological and pathological processes includ-
ing inflammation, tumour growth and metastatic progression [47], reinforced by upregulation
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of proteolytic ADAMs in both tumour tissues and cancer cell lines [48–50]. Correlations exist
between levels of specific ADAMs and parameters of tumour progression, implying that these
sheddases are implicated in the process of cancer development and the dissemination of meta-
static tumour cells [51]. ADAMs are now emerging as potential cancer biomarkers for aiding
cancer diagnoses and predicting patient outcome [52]. In addition, selective ADAM inhibitors
have promising anti-tumourigenic effects in in vitro and in vivo studies and are progressing
into clinical trials [53].
Here we demonstrate that the cellular sheddases, ADAM 10 and 17, are upregulated in a
MCPyV ST-dependent manner. Work highlights the essential role of ADAM sheddases in
MCPyV ST-mediated disruption of cell adhesion leading to enhanced cell dissociation and
motility. This suggests that ADAM protein expression may be a novel biomarker of MCC
prognosis and inhibiting ADAM activity may provide a novel opportunity for targeted inter-
ventions for disseminated MCC.
Results
MCPyV ST expression induces cell dissociation by disrupting cell junctions
Cell-cell adhesion and cell interaction to the extracellular matrix is required for tissue integrity
[54]. Disrupting cell-cell adhesion enhances cell scattering, which is essential to initiate cell
migration and metastatic spread [55]. To determine whether MCPyV ST expression affects the
integrity of cell junctions, EGFP and EGFP-ST transfected HEK 293 cells were stained with an
Alpha-E-catenin-specific antibody. Alpha-E-catenin, which is predominantly expressed at the
plasma membrane mediating cell adhesion and its breakdown impliess a loss of structural
integrity at cell junctions [56]. Results demonstrate that Alpha-E-catenin in control EGFP-
expressing cells primarily localised to the plasma membrane, in contrast a reduced and incom-
plete plasma membrane localisation is observed in EGFP-ST-expressing cells, indicative of
diminished cell-cell adhesion (Fig 1A). A similar result was also observed upon inducible
MCPyV ST expression in a HEK 293 FlpIn-derived cell line (i293-ST) [30] (S1 Fig). In addi-
tion, immunoblotting these cell lysates showed a decrease in Alpha-E-catenin protein levels
(S1 Fig). Quantification of Alpha-E-catenin levels at the plasma membrane in EGFP and
EGFP-ST-expressing cells was then performed using flow cytometry. Results validated the
immunofluorescence data demonstrating a reduction in Alpha-E-catenin levels upon MCPyV
ST expression (Fig 1B and 1C). To confirm the disruption of cell junctions, the levels of a sec-
ond cell adhesion-associated protein, Zona occludin 1 (ZO-1) [57], was compared in EGFP
versus EGFP-ST-expressing cells. Consistent with the reduction in Alpha-E-catenin levels,
immunoblot analysis showed a significant decrease in ZO-1 expression upon MCPyV ST
expression (Fig 1D and 1E). Together, these results provide the first indication that MCPyV
ST dysregulates cell-cell adhesion.
Loss of cell junction integrity enhances the ability of a cell to migrate and dissociate from its
primary site. To assess whether MCPyV ST induces cell dissociation and scatter, a cell scatter
assay was performed as previously described [58]. Here EGFP and EGFP-ST transfected HEK
293 cells were incubated in low serum to induce aggregation, upon reintroduction of serum
cells were fixed and stained with DAPI at 6 hourly intervals and clusters of cells were analysed
to quantify the distance between each cell nucleus (Fig 1F). Results show that EGFP control
cells scarcely dissociate, instead remaining in cell clusters. In contrast, MCPyV ST-expressing
cells dissociated significantly from their initial cell clusters. Similar results were also observed
in the MCPyV negative cell line MCC13, transfected with either EGFP or EGFP-ST expression
constructs (S1 Fig), although results in MCC13 cells were less pronounced than in HEK 293
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Fig 1. MCPyV ST expression induces cell dissociation by disrupting cell junctions. (A) HEK-293 cells were
transfected with 1 μg of pEGFP or pEGFP-ST expression plasmids. 24 h later cells were fixed and GFP fluorescence
analysed by direct visualisation, whereas endogenous Alpha-E-catenin was identified by indirect immunofluorescence
using a specific antibody. (B) EGFP or EGFP-ST transfected HEK-293 cells were harvested and stained with an Alpha-
E-catenin specific antibody and Alexa-Fluor-tagged secondary antibody. Mean fluorescence intensity was analyzed
using FlowJo software (C) Fold difference of cell surface staining was calculated using three replicates per experiment,
MCPyV ST enhances cell dissociation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007276 September 6, 2018 5 / 27
cells. These results suggest that MCPyV ST expression can lead to the breakdown of cell junc-
tions enhancing cell dissociation.
MCPyV ST expression affects the levels of ADAM proteins
Cellular sheddases function predominantly in the ectodomain cleavage of various membrane-
bound proteins, including cell adhesion molecules. Therefore, to identify potential cellular
sheddases induced upon MCPyV ST expression, we re-analysed a previously published
SILAC-based quantitative proteomic dataset which determined alterations in the host cell pro-
teome upon inducible MCPyV ST expression in a HEK 293 FlpIn-derived cell line (i293-ST)
[30]. MCPyV ST expression led to an increase in the levels of two specific cellular sheddases,
namely ADAM 10 and 17 proteins by 7.6 and 4.3 fold, respectively (S1 Fig). To confirm an
increase in ADAM protein levels upon MCPyV ST expression, cell lysates of uninduced and
induced i293-ST cells were analysed by immunoblotting. Results demonstrated a significant
increase in ADAM 10 and 17 mature protein levels, compared to ADAM TS1 (Fig 2A). Densi-
tometry-based quantification of the immunoblot analysis showed an increase in the mature
forms of ADAM 10 and 17 expression of 6 and 4 fold, respectively (Fig 2B). A similar fold
increase was also observed in MCC13 cells, transfected with either EGFP or EGFP-ST expres-
sion constructs (Fig 2C and 2D). The increase observed in ADAM protein levels occurs at the
transcriptional level, as RT-qPCR showed significant changes in the mRNA levels of both
ADAM proteins upon MCPyV ST expression in both HEK 293 and MCC13 cells (Fig 2E), cor-
relating with recent results showing MCPyV ST can dynamically alter the transcriptome of
human cells [26].
To further investigate the differential expression of ADAM 10 and 17 proteins in the con-
text of MCC, multicolour immunochemistry analysis was performed on formalin-fixed, paraf-
fin-embedded (FFPE) sections of primary MCC tumours. Sections were stained with ADAM
10 and 17, cytokeratin 20 (CK20) (a marker widely used to distinguish MCC) and MCPyV LT
specific antibodies. An isotyped-matched control was also used as a negative control. CK20
staining confirmed MCC status of the sections and results show increased levels of ADAM 10
and 17 expression coincident with LT staining in regions of both MCPyV-positive MCC
tumours (Fig 3A). Moreover, immunoblot analysis was performed on cell lysates of two unre-
lated MCPyV-positive MCC tumour samples comparing protein levels against a negative con-
trol non-tumour cadaveric skin sample. Results again demonstrated a similar increase in both
ADAM 10 and ADAM 17 protein levels in MCC tumour samples compared to control, which
was MCPyV negative as indicated by the lack of ST and LT expression (Fig 3B and 3C). More-
over, we compared the MCPyV-negative MCC13 cell line versus two MCPyV-positive cells
lines, WAGA and PeTa. Similar results were observed showing that the presence of MCPyV
ST increases ADAM 10 and 17 protein levels (S1 Fig). Immunoblot analysis was also per-
formed on cellular lysates of the MCPyV-positive MCC cell line, WAGA, transduced with
lentiviruses containing a shRNA scrambled control or shRNA targeting ST, as previously
n = 3 by a two-tailed t-test with unequal variance,  = p 0.0001. (D) HEK 293 cells were transfected with EGFP
and EGFP-ST expression plasmids for 48 hours. Immunoblot analysis was performed on the cellular lysates and
analysed with Alpha-E-catenin and ZO-1 specific antibodies. GAPDH was used as a measure of equal loading and the
2T2 hybridoma was used to confirm MCPyV ST expression. (E) Densitometry quantification of immunoblots was
carried out using the Image J software and is shown as a percentage relative to the loading control, GAPDH. Data
analysed using three replicates per experiment, n = 3 and statistical analysis using a two-tailed t-test with unequal
variance,  = p<0.0001. (F) EGFP or EGFP-ST transfected HEK 293 cells were serum starved for 24 hours to induce
aggregate formation. Upon reintroduction of serum, cells were fixed and stained with DAPI at 6 hourly intervals.
Images were analysed using Image J to quantify the distance between each cell nucleus. Data analysed using three
replicates per experiment, n = 50 cells, by a two-tailed t-test with unequal variance,  = p 0.0001.
https://doi.org/10.1371/journal.ppat.1007276.g001
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Fig 2. MCPyV ST expression increases the levels of ADAM proteins. (A) i293-ST cells remained uninduced or were incubated for 48
hours in the presence of doxycycline hyclate or (C) MCC13 cells were transfected with 1μg of pEGFP or pEGFP-ST for 12 hours. Cell
lysates were then probed with ADAM 10-, ADAM 17- and ADAM TS1-specific antibodies. GAPDH was used as a measure of equal
loading, the 2T2 hybridoma was used to confirm MCPyV ST expression. (B and D) Densitometry quantification of immunoblots was
carried out using the Image J software and is shown as a percentage relative to the loading control, GAPDH. Data analysed using three
replicates per experiment, n = 3 and statistical analysis using a two-tailed t-test with unequal variance,  = p<0.001,  = p<0.0001.
(E) Total RNA was extracted from EGFP or EGFP-ST transfected (i) HEK 293 and (ii) MCC13 cells and relative transcript levels were
MCPyV ST enhances cell dissociation
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described [31]. Results demonstrated that MCPyV ST depletion did not affect MCPyV LT lev-
els but led to a reduction in ADAM 10 and ADAM 17 protein levels. Conversely, ST depletion
leads to increased Alpha-E-catenin levels (Fig 3D). To confirm these observations and deter-
mine if ADAM 10 transcripts are significantly increased in MCPyV-positive MCC compared
with MCPyV-negative MCC, gene expression profiles for a total of ninety-four patients were
obtained from a publicly available dataset (accession number GSE39612 [9]). Bioinformatic
analysis identified a significant increase (2.5 fold, p = 0.03) in ADAM 10 expression in
MCPyV-positive MCC compared with MCPyV-negative MCC control samples. Moreover, a
similar analysis was performed to analyse ADAM protein expression in control GFP versus
MCPyV ST expressing cell datasets (accession number GSE79968) [26]. A significant increase
in both ADAM 10 (p =<0.0001) and ADAM 17 (p = <0.0001) was observed upon 48 hours
MCPyV ST expression. Together these data suggest that ADAM 10 and 17 protein levels are
increased upon MCPyV ST expression and in MCPyV-positive MCC tumour samples.
ADAM 10 and 17 localisation at the plasma membrane is increased upon
MCPyV ST expression
For active ADAM proteins to cleave their chosen substrate, they are required to be present at
the same subcellular location [59]. As adhesion molecule receptors are localised at the plasma
membrane, we next determined whether MCPyV ST enhancement of ADAM 10 and 17 pro-
tein levels led to their accumulation at the plasma membrane [60]. HEK 293 cells transfected
with EGFP or EGFP-ST were fixed and stained for endogenous ADAM 10 and ADAM 17 in
non-permeabilised cells. MCPyV ST-expressing cells showed increased levels of both ADAM
10 and 17 proteins at the plasma membrane, in comparison to the EGFP control cells (Fig 4A).
To confirm these results, cell surface accumulation of ADAM proteins was measured by sur-
face biotinylation assays in EGFP versus EGFP-ST expressing HEK 293 cells. Immunoblotting
of surface biotinylated proteins confirmed that MCPyV ST expression specifically increased
the plasma membrane levels of ADAM 10 and 17 proteins, in contrast the control cell surface
protein, CD71, showed no such increase (Fig 4B). Densitometry-based quantification of the
immunoblot analysis showed a significant increase in both ADAM 10 and 17 accumulation at
the plasma membrane by 5 fold and 2.5 fold, respectively (Fig 4C). Further validation was per-
formed using flow cytometry with ADAM 10- and ADAM 17-specific antibodies (Fig 4D and
4E). Notably however, both assays showed a greater accumulation of ADAM 10 compared to
ADAM 17 at the cell surface. Together, these results suggest that MCPyV ST expression results
in the accumulation of cellular sheddases, primarily ADAM 10, at the plasma membrane.
ADAM 10 is required for MCPyV ST-induced cell junction disruption
To determine whether ADAM protein accumulation at the plasma membrane is implicated in
the observed disruption of cell junctions upon MCPyV ST expression, EGFP and EGFP-ST
HEK 293-expressing cells were incubated in the absence or presence of two distinct ADAM
protease inhibitors. MTS assays identified non-cytotoxic concentrations of an ADAM 10-spe-
cific inhibitor (GI254023X) and dual ADAM 10/17 inhibitor (TAPI-2) (S2 Fig), no specific
ADAM 17 inhibitor is commercially available. Following a 24 hour incubation period, cells
were fixed and non-permeabilised cells stained with an Alpha-E-catenin-specific antibody. As
previously shown in Fig 1, incomplete staining of the cell junctions was observed in MCPyV
analysed by qRT-PCR using GAPDH as a reference. Fold increase was determined by ΔΔCt and statistical significance analysed using a
non-paired t-test,  = p<0.001,  = p<0.01.
https://doi.org/10.1371/journal.ppat.1007276.g002
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Fig 3. ADAM 10 and 17 levels are dysregulated in MCC tumour samples. (A) FFPE sections of primary MCC
tumours were stained with CK20, MCPyV LT and ADAM 10- or ADAM 17-specific antibodies or an isotype negative
control. Sections were then incubated with Alexa Fluor labelled secondary antibodies and analysed using a Zeiss
LSM880 confocal laser scanning microscope. (B) Immunoblot analysis was performed on the cellular lysates of two
independent MCC tumour samples and a negative control non-tumour cadaveric skin sample using ADAM 10- or
ADAM 17-specific antibodies. GAPDH was used as a measure of equal loading, the 2T2 hybridoma was used to
confirm MCPyV ST expression and the CM2B4 antibody used to confirm MCPyV tLT expression. (C) Densitometry
quantification of immunoblots was carried out using the Image J software and is shown as a percentage relative to the
MCPyV ST enhances cell dissociation
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ST-expressing cells, compared to control EGFP cells. However, retention of the cell junctions
was observed in the presence of both the ADAM 10-specific and dual ADAM 10/17 inhibitors,
implying that inhibition of ADAM sheddase activity, and specifically ADAM 10, is sufficient
to prevent MCPyV ST-induced breakdown of cell-cell junctions (Fig 5A). Importantly, there
was no observed change in the cell junction staining in EGFP control cells after incubation
with either inhibitor. The inhibition of MCPyV ST-induced cell junction breakdown was also
confirmed by quantifying the cell surface levels of Alpha-E-catenin using flow cytometry in
EGFP versus EGFP-ST-expressing cells. Results demonstrated increased levels of Alpha-E-
catenin expression at the cell surface upon addition of the inhibitors (Fig 5B). Notably, taking
into consideration the greater accumulation of ADAM 10 over ADAM 17 at the plasma mem-
brane in MCPyV ST-expressing cells and no enhancement of Alpha-E-catenin expression at
cell junctions in the presence of the dual ADAM10/17 inhibitor over the ADAM 10 inhibitor
alone, these results suggest that ADAM 10 may be the main cellular sheddase required for
MCPyV ST-induced cell junction disruption.
ADAM 10 is required for MCPyV ST-induced cell dissociation
To confirm that ADAM 10 was required for the enhanced cell dissociation observed in MCPyV
ST-expressing cells, the cell scatter assay was repeated in EGFP control and MCPyV ST-
expressing cells, in the absence and presence of the ADAM 10 specific inhibitor, GI254023X, at
non-cytotoxic concentrations. Addition of GI254023X resulted in little change in the EGFP-
expressing control cells. However, a significant decrease in cell dissociation, over the course of
48 hours, was observed in the presence of GI254023X compared to DMSO-treated MCPyV ST-
expressing cells (Fig 6A). A similar level of cell dissociation inhibition was also observed using
the ADAM10/17 dual inhibitor, TAPI-2 (S3 Fig), showing that no enhancement of inhibition is
seen by targeting both ADAM 10 and 17. To confirm the specific role of ADAM 10 in MCPyV
ST-induced cell dissociation, siRNA-mediated depletion of ADAM 10 was performed in EGFP
and EGFP-ST-expressing HEK 293 cells (Fig 6B). Immunoblotting confirmed that MCPyV ST
depletion led to Alpha-E-catenin protein levels comparable to EGFP control cells (Fig 6B and
6C). Cell scatter assays were then repeated in EGFP control or MCPyV ST-expressing cells,
in the presence of either scrambled or ADAM 10-specific siRNAs. Depletion of ADAM 10
resulted in a similar reduction in cell dissociation levels observed with the specific ADAM 10
inhibitor (Fig 6D). These data therefore suggest that ADAM 10 is required for the increased
ability of cells to dissociate upon MCPyV ST expression.
ADAM 10 inhibition impedes the ability of MCPyV ST expressing cells to
migrate
ADAM-mediated shedding of cell adhesion molecules may also stimulate cell signalling path-
ways to induce cell motility [30, 31]. Therefore, we next examined if ADAM proteins have any
loading control, GAPDH. Data analysed using three replicates per experiment, n = 3 and statistical analysis using a
two-tailed t-test with unequal variance,  = p 0.0001,  = p<0.001,  = p<0.01. (D) (i) The MCPyV-positive
MCC cell line, WAGA, was transduced with lentivirus expressing a scrambled shRNA or ST-targetting shRNA. Upon
ST depletion cell lysates were probed with ADAM 10-, ADAM 17- or Alpha-E-catenin specific antibodies. GAPDH
was used as a measure of equal loading, the 2T2 hybridoma was used to confirm MCPyV ST expression and the
CM2B4 antibody used to confirm MCPyV tLT expression. These samples have been previously used to assess
expression of actin-associated proteins [31]. (ii) Densitometry quantification of immunoblots was carried out using the
Image J software and is shown as a percentage relative to the loading control, GAPDH. Data analysed using three
replicates per experiment, n = 3 and statistical analysis using a two-tailed t-test with unequal variance,  =
p<0.0001,  = p<0.001.
https://doi.org/10.1371/journal.ppat.1007276.g003
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Fig 4. ADAM 10 and 17 localisation at the cell surface is increased upon MCPyV ST expression. (A) HEK 293 cells were transfected with
1 μg of EGFP or EGFP-ST expression plasmids. 24 hours later cells were fixed and GFP fluorescence analysed by direct visualisation, whereas
endogenous (i) ADAM 10 and (ii) ADAM 17 were identified by indirect immunofluorescence using specific antibodies. (B) Surface
biotinylation experiments were performed in EGFP or EGFP-ST transfected HEK 293 cells, lysates were probed for ADAM 10, ADAM 17 and
CD71 as a surface marker control. (C) Densitometry of immunoblots was performed using ImageJ software. Data analysed using three replicates
per experiment, n = 3 and statistical analysis using a two-tailed t-test with unequal variance,  = p<0.001,  = p<0.01. (D) EGFP or EGFP-ST
transfected HEK 293 cells were harvested and stained with (i) ADAM 10-, (ii) ADAM 17- and CD71-specific antibodies. Mean fluorescence
MCPyV ST enhances cell dissociation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007276 September 6, 2018 11 / 27
intensity was analyzed using FlowJo software. (E) Fold difference of cell surface staining was calculated using three replicates per experiment,
n = 3 by a two-tailed t-test with unequal variance,  = p<0.001 and  = p<0.01.
https://doi.org/10.1371/journal.ppat.1007276.g004
Fig 5. ADAM 10 is required for MCPyV ST-induced cell junction disruption. (A) HEK 293 cells were transfected with 1 μg of (i) EGFP or (ii)
EGFP-ST expression plasmids and grown in the absence or presence of GI254023X or TAPI-2 inhibitors. 24 hours later cells were fixed and EGFP
fluorescence analysed by direct visualisation, whereas endogenous Alpha-E-Catenin was identified by indirect immunofluorescence using a specific
antibody. The top panel for both (i) and (ii) is the same as Fig 1A. (B) EGFP or EGFP-ST transfected HEK 293 cells were grown in the absence or
presence of GI254023X or TAPI-2 inhibitors for 24 hours, then harvested and stained with an Alpha-E-catenin specific antibody and Alexa-Fluor-
tagged secondary antibody. Mean fluorescence intensity was analyzed using FlowJo software. Fold difference of cell surface staining was calculated
using three replicates per experiment, n = 3 by a two-tailed t-test with unequal variance,  = p<0.001 and  = p<0.01.
https://doi.org/10.1371/journal.ppat.1007276.g005
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Fig 6. ADAM 10 is required for MCPyV ST-induced cell dissociation. (A) EGFP or EGFP-ST transfected HEK 293
cells were incubated with the ADAM 10 specific inhibitor, GI254023X (50 μM), then serum starved for 24 hours to
induce aggregate formation. Upon reintroduction of serum, cells were fixed and stained with DAPI at 24 hourly
intervals. Images were analysed using Image-J to quantify the distance between each cell nucleus. Data analysed using
three replicates per experiment, n = 50 cells, by a two-tailed t-test with unequal variance,  = p 0.0001. (B) HEK
293 cells were transfected with 1 μg EGFP or EGFP-ST in the presence of either scramble or ADAM 10-specific
siRNAs. After 24 hours, cell lysates were probed using ADAM 10- and Alpha-E-catenin specific antibodies. GAPDH
was used to measure equal loading. 2T2 was used to probe for MCPyV ST expression. (C) Densitometry of
MCPyV ST enhances cell dissociation
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downstream impact on the motility and migratory potential of MCPyV ST-expressing cells.
Here, the migrating potential of EGFP control and EGFP-ST HEK 293 and MCC13-expressing
cells were assessed using Incucyte kinetic live cell imaging, in the absence or presence of non-
cytotoxic concentrations of the ADAM 10-specific (GI254023X) and dual ADAM 10/17
(TAPI-2) inhibitors. Incubation of the ADAM 10 (GI254023X) inhibitor showed a slight
but insignificant decrease in the motility of EGFP control cells, implying that any changes
observed in migratory rates of MCPyV ST expression cells is not due to changes in cell viability
or cytotoxicity. In contrast, ADAM 10 inhibition resulted in a significant decrease in the dis-
tance travelled of MCPyV ST-expressing cells, reminiscent of control cell migration (Fig 7A).
A similar trend was also observed with the dual ADAM 10/17 (TAPI-2) inhibitor (Fig 7B), sug-
gesting that inhibition of ADAM 10 alone was sufficient to repress the MCPyV ST-induced
cell migratory phenotype. To validate the use of ADAM-specific inhibitors, similar live cell
imaging motility assays were also performed in ADAM 10-depleted EGFP and MCPyV ST-
expressing HEK 293 cells, which resulted in a reduction in the motility of MCPyV ST-express-
ing cells, to levels similar to control EGFP-expressing cells (Fig 7C).
To demonstrate that ADAM 10 is required for cell motility and migration of MCPyV-posi-
tive MCC cell lines, haptotaxis migration assays were performed. This assay investigates the
three-dimensional migration of cells towards a chemoattractant across a permeable chamber.
Two MCPyV-positive MCC cell lines, WAGA and PeTa, were incubated in the absence or
presence of the ADAM 10 inhibitor (GI254023X) at non-toxic concentrations assessed by
MTS assay (S4 Fig) or upon siRNA-mediated scramble or ADAM 10-specific depletion. After
treatment, cells were allowed to migrate for 24 h before migration was assessed by immunoflu-
orescent staining of cells that had migrated into the chambers. Results showed that migration
of MCPyV positive MCC cell lines were significantly reduced compared to control, upon treat-
ment with GI254023X (Fig 8A) or upon ADAM 10 depletion (Fig 8B), suggesting that MCPyV
positive MCC cell line migration is ADAM 10 dependent. Together, these results suggest that
ADAM 10 is required for MCPyV ST-mediated enhanced cell motility and migration.
Discussion
MCPyV ST has emerged as the major transforming factor in MCPyV-positive MCC. Recently
we reported a potential role for MCPyV ST in MCC metastasis, whereby ST cultivates a pro-
migratory cell phenotype by destabilising microtubules [30], inducing filopodia formation
[31] and modulating cellular chloride channels [32]. Cancer metastasis occurs via a series of
complex events that are collectively known as the invasion-metastasis cascade [61]. The apex
event in the metastatic cascade is broadly accepted to be mediated by an EMT, providing
tumour cells increased motility allowing invasion of the ECM. Most oncoviruses have been
shown to manipulate the EMT axis, for example, human papillomavirus 16, Epstein-Barr virus
(EBV), hepatitis B virus and the polyomavirus simian virus 40 have all been shown to induce
metastasis, through a variety of mechanisms including; cellular adhesion complexes, cytoskele-
tal reorganisation and gene expression modulation [62–65]. EBV latent membrane protein-1,
for example orchestrates EMT via several different routes, including the transcriptional
immunoblots was performed using ImageJ software. Data analysed using three replicates per experiment, n = 3 and
statistical analysis using a two-tailed t-test with unequal variance,  = p<0.001. (D) HEK 293 cells were transfected
with 1 μg EGFP or EGFP-ST in the presence of either scramble or ADAM 10-specific siRNAs, then serum starved for
24 hours to induce aggregate formation. Upon reintroduction of serum, cells were fixed and stained with DAPI at 6
hourly intervals. Images were analysed using Image-J to quantify the distance between each cell nucleus. Data analysed
using three replicates per experiment, n = 50 cells, by a two-tailed t-test with unequal variance,  = p 0.0001.
https://doi.org/10.1371/journal.ppat.1007276.g006
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Fig 7. ADAM 10 inhibition impedes the ability of MCPyV ST expressing cells to migrate. (A) EGFP or EGFP-ST transfected (i) HEK 293 or
(ii) MCC13 cells were incubated with DMSO or the ADAM 10 specific inhibitor, GI254023X (50 μM). (B) EGFP or EGFP-ST transfected (i)
HEK 293 or (ii) MCC13 cells were incubated with DMSO or the ADAM 10/17 dual inhibitor, TAPI-2 (50 μM). (C). HEK 293 cells were
transfected with 1 μg EGFP or EGFP-ST in the presence of either scramble or ADAM 10-specific siRNAs. After 24 hours, cell motility was
analysed using an IncuCyte Zoom-kinetic live cell imaging system. Images were taken every 30 minutes for a 24 hour period. The movement of
cells were then tracked using Image J software and the average distance travelled was measured in μm (n = 50 per condition) and significance
was tested using a 3-tailed Student’s t-test,  = p<0.001 and  = p<0.01.
https://doi.org/10.1371/journal.ppat.1007276.g007
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repression of E-cadherin via activation of DNA methyltransferases [66] and increased expres-
sion of the pleiotropic EMT transcription factors, Twist and Snail [67, 68].
Here we expand on recent observations suggesting that MCPyV ST can trigger elements
of the EMT and initiate the invasion-metastasis cascade, by demonstrating that MCPyV ST
induces cell-surface expression of cellular sheddases, specifically ADAM 10 and 17. More-
over, we show that MCPyV ST-mediated induction of ADAM 10 is required for MCPyV ST-
induced cell-cell junction disruption which in turn enhances cell dissociation, migration and
invasion. Although we focus herein on the link between MCPyV ST induction of ADAM
proteins in metastatic spread, it must be noted that activation of ADAM10 may also serve
in MCPyV fitness. Fibroblasts are a target of MCPyV infection [69] and is it known that
MCPyV is shed from the surface of the skin, it is plausible therefore ADAM10 expression be
a way for infected fibroblasts to migrate into the epidermis or hair follicle so the virus can be
shed into the environment. How MCPyV ST regulates ADAM 10 expression is not yet clear,
although results suggest this is likely to be at the transcriptional level. The ADAM 10 pro-
moter contains functional binding sites for Sp1 and USF [70] and has been reported to be
activated by numerous transcriptional activators including, XBP1, JUN, ACAD8, PPARG,
SCAND1 and ITGB3BP [71, 72]. Interestingly, ACAD8, PPARG and ITGB3BP all appear in
Fig 8. ADAM 10 is required for the motility of MCC cells. (A) MCPyV positive MCC cell lines, PeTa and WAGA,
were incubated with DMSO or the ADAM 10 specific inhibitor, GI254023X (50 μM). Cells were then transferred into
migration wells and allowed to migrate from serum-free to 10% FBS conditions for 24 hours. Migratory cells were
stained and measured at 560 nm to quantify migration. Average cell migration was calculated and significance tested
using a two-tailed Student’s t-test (n = 3),  = p<0.001. (B) (i) PeTa and WAGA cells were transfected with either
scramble or ADAM 10-specific siRNAs and cell lysates probed to confirm successful knockdown with an ADAM
10-specific antibody. GAPDH was used as loading control. 2T2 was used to probe for MCPyV ST expression. (ii)
Control and ADAM 10-depleted cells were then transferred into migration wells and allowed to migrate from serum-
free to 10% FBS conditions for 24 hours. Migratory cells were stained and measured at 560 nm to quantify migration.
Average cell migration was calculated and significance tested using a two-tailed Student’s t-test (n = 3),  =
p<0.0001,  = p<0.001.
https://doi.org/10.1371/journal.ppat.1007276.g008
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a recent RNA-seq data set of MCPyV ST-induced genes [26], raising the possibility that these
transcription factors may be responsible for MCPyV ST-mediated induction of ADAM 10
expression.
There is a growing appreciation for the role played by ADAM proteins in numerous
human diseases [73], including Alzheimer’s disease, cardiovascular disease, rheumatoid arthri-
tis and cancer [52]. The best characterised sheddase in terms of cancer aetiology is ADAM 17,
which is implicated in the development and progression of numerous neoplasms [74]. ADAM
17 came to prominence due to its ability to shed the soluble form of the inflammatory cyto-
kine, TNFα from it precursor product [75, 76], however, despite TNFα being widely impli-
cated in tumour development and progression, it is the ability of ADAM 17 to hydrolyse and
promote the release of epidermal growth factor receptor (EGFR)/human EGFR (HER) precur-
sor ligands that features most frequently in published studies. For example, ADAM 17-medi-
ated shedding of TGFβ is implicated in breast [77, 78] and renal [79] cancer progression.
Moreover, release of the transmembrane protein with EGF and two follistatin motifs
(TMEFF2) increases prostate cancer cell motility [80]. We observed significant upregulation
of ADAM 17 in response to MCPyV ST expression and in MCC tumours, however, compari-
son of ADAM 10 and ADAM 10/17 inhibitor experiments suggest that ADAM 17 is not
required for the EMT-associated phenotypes observed following expression of MCPyV ST.
This supposition is supported by bioinformatic analysis of MCPyV-positive MCC compared
with MCPyV-negative MCC tumours, which identified significantly increased expression of
ADAM 10, but not ADAM 17 in 94 patient samples. The role of ADAM 10 in cancer metasta-
sis is less clear, however emerging evidence suggests that ADAM 10 maybe cell-type specific,
driving motility and invasion in breast [81], pancreatic [82], melanoma [83] and bladder [84]
metastasis compared with primary tumours, but having alternative effects on proliferation in
other tissue types. Interestingly, while HER ligand release is generally ADAM-specific, overex-
pression of individual ADAM proteins drives promiscuity in terms of ligand cleavage [85].
This raises the possibility that MCPyV ST-induced overexpression may enable ADAM 10 to
cleave proteins ordinarily regulated by other sheddases, a scenario that needs to be considered
when investigating downstream targets of ADAM 10 in MCC.
Generally, metastasised MCC is treated with various regimens of broad-spectrum chemo-
therapy agents. However, metastatic MCC responses are not robust and often associated with
high toxicity in elderly patients [86]. Response rates range from 52% to 61% in the distant met-
astatic setting, with progression-free survival (PFS) and overall survival typically measured in
months [87–89]. One of the strongest predictors for survival is a high level of intratumoural
CD8+ T cells most frequently observed in MCPyV-positive MCC [90, 91]. MCPyV-specific
CD8+ T cells express high levels of PD-1 and TIM-3 (the T cell immunoglobulin and mucin
domain-3), which prompted immunotherapy-based clinical trials in MCC patients with the
anti-PD-1 antibodies, pembrolizumab [92] and avelumab [93]. Both phase 2 trials reported
encouraging and positive response rates with improved PFS, leading to pembrolizumab being
listed as a treatment option for late-stage MCC in the National Comprehensive Cancer Net-
work 2017 guidelines and avelumab being granted accelerated FDA approval as a first-line
treatment for metastatic MCC. Whilst promising, around half of the patients involved in these
clinical trials derived limited benefit from either drug [94], indicating the importance of identi-
fying additional agents to use in combination with anti-PD-1 antibodies. This approach may
have exciting possibilities for ADAM 10/17 inhibitors, as TIM-3 is shed by both ADAM 10
and 17 and ADAM 10 cleaves MHC-I [95]. Notably, monoclonal antibody blocking of TIM-3
reduced PD-1 expression and increased cytokine production [96], indicating that TIM-3 func-
tions to dampen the immune system [97]. Therefore, ADAM 10 and 17 inhibitors may stimu-
late the immune system by reducing TIM-3 cleavage.
MCPyV ST enhances cell dissociation
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007276 September 6, 2018 17 / 27
One of the most widely characterised ADAM inhibitory compounds is INCB3619 (Incyte),
a dual ADAM 10 and 17 inhibitor which inhibits the catalytic activity of ADAM proteins by
chelating zinc at the active site [53]. In vitro studies using breast and small cell lung cancer cell
lines, have shown that INCB3619 reduced the cleavage of HER2 and amphiregulin, thereby
sensitising cells to the EGFR tyrosine kinase inhibitor, gefintinib or a dual EGFR/HER2 inhibi-
tor, GW2974 [98–100]. These observations have also been extended in animal models where
INCB3619 shows anti-cancer activity against malignancies of the lung (non-small cell), breast,
head and neck [98, 99]. Notably, a structurally similar compound with enhanced pharmoki-
netic properties, IMCB7839 (Aderbasib), has undergone phase I/II clinical trials in patients
with HER2-positive breast cancer, in combination with Herceptin (trastuzumab). Results
showed improved clinical responses in a subset of HER2-positive metastatic breast cancer
patients, expressing the p95 form of HER2 [52, 98]. At present, additional phase I/II clinical
trials are ongoing, for example in patients with diffuse large B cell non-Hodgkin lymphoma
using INCB7839 in combination with the monoclonal antibody rituximab [52]. Therefore,
given our data showing a significant upregulation of ADAM 10/17 in MCC cell lines and
tumours and the integral role played by ADAM 10 in MCPyV ST-mediated enhanced cell dis-
sociation and invasion, selective inhibitors of ADAM 10 and 17 may prove to be potent novel
therapeutics when given in combination with immune checkpoint inhibitors for the treatment
of advanced MCC.
Materials and methods
Plasmids, siRNAs, antibodies and chemicals
The expression vectors for EGFP-ST has been previously described [23, 30, 31]. MCPyV ST-
tagging shRNA plasmids were kindly provided by Dr Masa Shuda, Pittsburgh. ADAM 10 and
17-specific siRNAs were purchased from Dharmacon. Antibodies against ADAM 10, ADAM
17, ADAM TS1, and GAPDH were purchased form Abcam and used at a dilution range of
1:100–1:500, the ZO-1, CD71 and Alpha-E-catenin antibodies were purchased from Cell sig-
nalling and used at 1:100 dilution. The 2T2 hybridoma was provided by Dr Buck, National
Cancer Institute, Bethesda, MD. All antibodies used for immunofluorescence were diluted
1:200. ADAM 10 specific inhibitor, GI254023X and ADAM 10/17 dual inhibitor, TAPI-2
where purchased from TOCRIS and Merck Millipore, respectively. Cell toxicity was measured
using a MTS-based CellTiter 96 AqueousOne Solution Proliferation assay (Promega), as previ-
ously described [101].
Mammalian cell culture
HEK-293 Flip-In cell line was purchased from Invitrogen. i293-ST, i293-GFP, and i293-GFP-
ST cell lines were derived from HEK-293 Flip-Ins using manufacturer’s protocol as previously
described [23]. HEK-293 cells were obtained from ECACC and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% foetal bovine serum (FBS) and 1%
penicillin/streptomycin as previously described [102]. The MCPyV negative cell line MCC13
(ECACC) and positive MCC cell lines, WAGA and PeTa (ATCC), were grown in RPMI 1640
(Sigma) supplemented with 10% FBS. ST-FLAG, EGFP and EGFP-ST expression was induced
from i293-ST, i293-GFP, and i293-GFP-ST cells respectively with 2 μg/ml Doxycycline hyclate
for up to 48 hours. Cells were plated into 6-well plates and transfections routinely used 1 μg
plasmid DNA and Lipofectamine 2000 (Life Technologies) or 5 μg plasmid DNA and nucleo-
fection (Lonza) following the manufacturer’s instructions.
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Immunofluorescence
Immunofluorescence was carried out as previously described [103]. If appropriate, cells were
treated with inhibitors for24 hours prior to fixation. Cells were viewed on a Zeiss LSM880 con-
focal laser scanning microscope under an oil-immersion 63x objective lens. Images were ana-
lysed using the LSM imaging software as previously described [104].
Flow cytometric detection of cell-surface molecules
EGFP and EGFP-ST-transfected cells were detached using Versene (Sigma-Aldrich). The har-
vested cells were washed with ice-cold PBS and resuspended at 2x106 cells/ml in freshly made
staining buffer (PBS, 10% FCS, 3% BSA). Cells were then incubated with appropriate dilutions
of primary antibody or staining buffer for 1 hour at room temperature in the dark, washed
with staining buffer and then incubated with Alexa-Fluor-tagged secondary antibodies or
staining buffer for 1 hour at room temperature. Cells were washed twice in PBS with centrifu-
gation (350x g, 5 min) and then analyzed by flow cytometry on a FACSCalibur, (BD Biosci-
ence, Wokingham, UK) and the data analyzed using FlowJo software (Tree Star, Ashland, OR,
USA).
Immunoblotting
Skin and MCC tumour biopsy samples were crushed using a pestle and mortar on dry ice,
and homogenised by sonication prior to lysis in RIPA buffer (50 mM Tris-HCl pH 7.6, 150
mM NaCl, 1% NP40), supplemented with protease inhibitor cocktail (Roche) as previously
described [105]. Proteins were separated by SDS-PAGE, transferred to nitrocellulose mem-
branes and probed with the appropriate primary and HRP-conjugated secondary antibodies.
Proteins were detected using EZ-ECL enhancer solution (Geneflow) as previously described
[106]. Densitometry was performed using ImageJ software.
qRT-PCR
RNA was extracted using TRIzol (Invitrogen) and DNase treated using the Ambion DNase-
free kit, as per the manufacturer’s instructions, before RNA (1μg) from each fraction was
reverse transcribed with SuperScript II (Invitrogen), as per the manufacturer’s instructions,
using oligo(dT) primers (Promega). 10ng of cDNA was used as template in SensiMixPlus
SYBR qPCR reactions (Quantace), as per manufacturer’s instructions, using a Rotor-Gene Q
5plex HRM Platform (Qiagen), with a standard 3-step melt program (95 ˚C for 15 seconds, 60
˚C for 30 seconds, 72 ˚C for 20 seconds) as previously described [107]. With GAPDH as inter-
nal control mRNA, quantitative analysis was performed using the comparative ΔΔCt method
as previously described [108].
Cell scatter assay
EGFP and EGFP-ST-transfected HEK 293 cells were seeded in DMEM containing 10% FBS
at a density of 2 × 104 per 35 mm culture dish. 18 hours later, cells were serum starved for 24
hours to induce aggregate formation. Upon reintroduction of serum, cells were fixed and
stained with DAPI at 6 hourly intervals and clusters of cells were imaged using a Zeiss LSM880
confocal laser scanning microscope using a 10x objective lens. Images were analysed using the
LSM imaging software to quantify the distance between each cell nucleus.
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Multicolour immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) sections from primary MCC tumours were pur-
chased from Origene and analysed as previously described [32]. Primary antibodies were:
FITC-conjugated anti-CK20 (Dako, dilution 1:50), MCPyV LT CM2B4 (Santa Cruz Biotech-
nology, dilution 1:125) and ADAM 10 and 17 (Abcam, dilution 1:250). An isotype-matched
irrelevant antibody was used as a negative control on sections of tissues in parallel, a rabbit
polyclonal isotype control antibody (Abcam) was used to match the ADAM 10 primary anti-
body. Sections were incubated with appropriate secondary antibodies labelled with different
fluorochromes (Alexa Fluor 546 IgG2B, 643 IgG2A, Invitrogen, and IgG (H+L)-TRITC, Jack-
son ImmunoResearch). All slides were mounted with Immuno-Mount and images were cap-
tured with a Zeiss LSM880 confocal laser scanning microscope.
Gene expression analysis
Metadata and pre-processed data (FPKM) were downloaded from Gene Expression Omnibus
(GSE79968) [26] and GSE39612 [9]. Data were normalised by the trimmed mean of M-values
methods using edgeR package to account for batch effects and differences in sequencing depth
among the samples using R/Bioconductor [109]. The differential expression analysis was per-
formed using the R Bioconductor packages, voom and limma.
Cell surface biotinylation assay
Cell surface biotinylation was performed using the Pierce Cell Surface Protein Isolation kit
(Thermo Scientific) according to the manufacturer’s protocol. Cells were incubated a cell-
impermeable, cleavable biotinylation reagent, EZ-LINK Sulfo-NHS-SS-Biotin, to label exposed
primary amines of proteins on the cell surface. After cell lysis, biotinylated cell surface proteins
were affinity-purified using NeutrAvidin Agarose Resin (Thermo Scientific). Precipitated pro-
teins were then analysed using immunoblotting with ADAM 10- and ADAM 17- specific anti-
bodies. A CD71-specific antibody was used as a suitable loading control.
Live cell imaging
Cell motility was analysed using an Incucyte kinetic live cell imaging system as directed by
the manufacturer. HEK293 cells or i293-GFP/i293-GFP-ST cells were seeded at a density of
25,000 cells per well of a 6 well plate, MCC13 cells were seeded at a density of 100,000 cells per
well of a 6 well plate. After 12 hours, the cells were transfected with 1 μg of DNA per well and/
or induced using doxycycline hyclate. For transfected cells, media was changed after 6 hours
(HEK-293 or derivatives) or 12 hours (MCC13). If appropriate, cells were treated with inhibi-
tors for 24h pre-imaging. Imaging was performed for a 24 hour period, with images taken
every 30 minutes. Cell motility was then tracked and analysed using ImageJ software.
Haptotaxis migration assay
Migration assays were performed using a CytoSelect 24-well Haptotaxis Assay Collagen coated
plates (Cell Biolabs, Inc), as directed by the manufacturer. All conditions were performed in
triplicate.
Supporting information
S1 Fig. MCPyV ST expression induces cell dissociation in HEK 293 and MCC13 cells. (A)
(i) i293-ST cells remained uninduced or were incubated for 24 h in the presence of doxycycline
hyclate. Cells were then fixed and endogenous Alpha-E-catenin was identified by indirect
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immunofluorescence using a specific antibody. (ii) Western blotting using a FLAG and Alpha-
E-catenin-specific antibodies confirm the expression of MCPyV ST in the induced i293-ST
sample and also demonstrate reduced Alpha-E-catenin levels. (B) EGFP or EGFP-ST trans-
fected MCC13 cells were serum starved for 24 hours to induce aggregate formation. Upon
reintroduction of serum, cells were fixed and stained with DAPI at 6 hourly intervals. Images
were analysed using Image-J to quantify the distance between each cell nucleus. Data analysed
using three replicates per experiment, n = 50 cells, by a two-tailed t-test with unequal variance,
 = p 0.001. (C) Summary of quantitative proteomic analysis previously published [30]
showing an increase in ADAM proteins and a decrease in cell junction associated protein lev-
els upon MCPyV ST expression. (D) Immunoblotting of MCPyV-negative MCC13 cells versus
MCPyV positive MCC cell lines, PeTa and WAGA, using ADAM 10- and ADAM 17-specific
antibodies. GAPDH was used as a measure of equal loading, the 2T2 hybridoma was used to
confirm MCPyV ST expression.
(TIF)
S2 Fig. Cell viability (MTS) assay for ADAM protein inhibitors. HEK 293 (A) and MCC13
(B) cells were treated with increasing concentrations of (i) ADAM 10 specific inhibitor,
GI254023X or (ii) ADAM 10/17 dual inhibitor, TAPI-2 for 24 hours. 20 μl of the MTS reagent
was added for 45 minutes and cell viability was measured at 492 nm using a plate reader.
(TIF)
S3 Fig. An ADAM 10/17 dual inhibitor inhibits MCPyV ST-induced cell dissociation.
EGFP or EGFP-ST transfected HEK 293 cells were incubated with the ADAM 10 and17 dual
inhibitor, TAPI-2 (50 μM), then serum starved for 24 hours to induce aggregate formation.
Upon reintroduction of serum, cells were fixed and stained with DAPI at 24 hourly intervals.
Images were analysed using Image-J to quantify the distance between each cell nucleus. Data
analysed using three replicates per experiment, n = 50 cells, by a two-tailed t-test with unequal
variance,  = p 0.0001.
(TIF)
S4 Fig. Cell viability (MTS) assay for ADAM 10 inhibitor in MCC cell lines. The MCPyV
positive MCC cell lines PeTa (A) and WAGA (B) cells were treated with increasing concentra-
tions of the ADAM 10 specific inhibitor, GI254023X. 20 μl of the MTS reagent was added for
45 minutes and cell viability was measured at 492 nm using a plate reader.
(TIF)
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